UBS Downgrades Cepheid Stock to 'Neutral' | GenomeWeb
NEW YORK (GenomeWeb News) — Investment bank UBS today downgraded Cepheid’s stock to ‘neutral’ from ‘buy.’
 
Cepheid’s shares have risen 135 percent since the start of the year and reached a new 52-week high yesterday when they reached $20.29. Shares closed at $20.17 that day.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.